Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob S Sellar

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
BMJ (Clinical Research Ed.)|March 12, 2010
Treatment for lymph node tuberculosisRob S Sellar, E L Corbett, Shirley D'Sa, et al.
British Journal of Haematology|April 25, 2018
Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003Rob S Sellar, Clare Rowntree, Ajay J Vora, et al.
British Journal of Haematology|April 21, 2018
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcomeRob S Sellar, Rosemary E Gale, Asim Khwaja, et al.
International Journal of Cardiology|May 17, 2024
The clonal hematopoiesis mutation Jak2<sup>V617F</sup> aggravates endothelial injury and thrombosis in arteries with erosion-like intimasRoberto Molinaro, Rob S Sellar, Amélie Vromman, et al.
British Journal of Haematology|March 12, 2015
BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patientsRob S Sellar, Falko Fend, Ayse U Akarca, et al.
British Journal of Haematology|April 11, 2016
Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatmentRob S Sellar, Laura Fraser, Asim Khwaja, et al.
Blood|December 16, 2014
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism statusRob S Sellar, Frederick Arce Vargas, Jake Y Henry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2017
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan AllograftsKile Green, Kim Pearce, Rob S Sellar, et al.
Blood|June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 TrialSteven Knapper, Abin Thomas, Robert K Hills, et al.
Blood|June 30, 2018
<i>PPM1D</i>-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cellsJosephine D Kahn, Peter G Miller, Alexander J Silver, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
BMJ (Clinical Research Ed.)|March 12, 2010
Treatment for lymph node tuberculosisRob S Sellar, E L Corbett, Shirley D'Sa, et al.
British Journal of Haematology|April 25, 2018
Relapse in teenage and young adult patients treated on a paediatric minimal residual disease stratified ALL treatment protocol is associated with a poor outcome: results from UKALL2003Rob S Sellar, Clare Rowntree, Ajay J Vora, et al.
British Journal of Haematology|April 21, 2018
Immunophenotypic analysis of cell cycle status in acute myeloid leukaemia: relationship to cytogenetics, genotype and clinical outcomeRob S Sellar, Rosemary E Gale, Asim Khwaja, et al.
International Journal of Cardiology|May 17, 2024
The clonal hematopoiesis mutation Jak2<sup>V617F</sup> aggravates endothelial injury and thrombosis in arteries with erosion-like intimasRoberto Molinaro, Rob S Sellar, Amélie Vromman, et al.
British Journal of Haematology|March 12, 2015
BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patientsRob S Sellar, Falko Fend, Ayse U Akarca, et al.
British Journal of Haematology|April 11, 2016
Cell cycle status in AML blast cells from peripheral blood, bone marrow aspirates and trephines and implications for biological studies and treatmentRob S Sellar, Laura Fraser, Asim Khwaja, et al.
Blood|December 16, 2014
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism statusRob S Sellar, Frederick Arce Vargas, Jake Y Henry, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 19, 2017
Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan AllograftsKile Green, Kim Pearce, Rob S Sellar, et al.
Blood|June 25, 2026
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 TrialSteven Knapper, Abin Thomas, Robert K Hills, et al.
Blood|June 30, 2018
<i>PPM1D</i>-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cellsJosephine D Kahn, Peter G Miller, Alexander J Silver, et al.
Pageof 4